Relapsing-Remitting Multiple Sclerosis: Ozanimod Study
We are studying how ozanimod may help limit brain changes in people with relapsing-remitting multiple sclerosis. The trial looks at its effects on disease activity, cognition, fatigue, and quality of life.
Sponsor: Ospedale San Raffaele S.r.l.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.